Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer



Status:Active, not recruiting
Conditions:Ovarian Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:1/5/2019
Start Date:September 27, 2010

Use our guide to learn which trials are right for you!

GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262

This phase III clinical trial studies two different dose schedules of paclitaxel to see how
well they work in combination with carboplatin with or without bevacizumab in treating
patients with stage II, III or IV ovarian epithelial cancer, primary peritoneal cancer, or
fallopian tube cancer. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work
in different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Bevacizumab is a type of drug called
a monoclonal antibody and blocks tumor growth by stopping the growth of blood vessels that
tumors need to grow. It is not yet known whether giving paclitaxel with combination
chemotherapy once every three weeks is more effective than giving paclitaxel once a week in
treating patients with ovarian, primary peritoneal, or fallopian tube cancer.

PRIMARY OBJECTIVES:

I. To determine if the weekly paclitaxel regimen increases the time until first progression
or death (progression-free survival [PFS]) compared to the every-3-week paclitaxel regimen in
women with primary stage II, III or IV epithelial ovarian, peritoneal or fallopian tube
cancer who are receiving carboplatin with or without bevacizumab.

SECONDARY OBJECTIVES:

I. To determine if the weekly paclitaxel increases the duration of overall survival compared
to the every-3-week paclitaxel when combined with carboplatin with or without bevacizumab.

II. To compare the weekly paclitaxel to the every-3-week paclitaxel with respect to the
incidence of severe or serious adverse events when it is combined with carboplatin with or
without bevacizumab.

III. To compare the weekly paclitaxel to the every-3-week paclitaxel with respect to
patients' self-reported quality of life (QOL) as measured by the Functional Assessment of
Cancer Therapy-Ovarian (FACT-O)-Trial Outcome Index (TOI), when paclitaxel is combined with
carboplatin with or without bevacizumab. (As of 02/08/2012, the QOL portion of this study is
complete; patients enrolled after this date will not have QOL assessments)

TERTIARY OBJECTIVES:

I. To evaluate single nucleotide polymorphisms (SNPs) associated with progression-free
survival and toxicity in advanced stage epithelial ovarian, peritoneal and fallopian tube
cancer using genome wide association studies (GWAS).* II. To evaluate genomic signatures in
tumor tissues which are predictive for patient survival in advanced stage epithelial ovarian,
peritoneal and fallopian tube cancer.* III. To evaluate the association between serum and
plasma biomarkers and response to anti-angiogenesis therapy in advanced stage epithelial
ovarian, peritoneal, and fallopian tube cancer.*

NOTE: *As of 02/08/2012, the translational research (TR) portion of this study is complete;
patients enrolled after this date will not have TR specimens collected.

IMAGING PRIMARY OBJECTIVES:

I. To determine whether larger changes in the tumor perfusion parameters from baseline
timepoint (T0) to early-therapy T2 are prognostic of higher progression-free survival (PFS)
rate at 6 months (PFS-6) from enrollment in patients treated with weekly or every-3-week
paclitaxel regimens, who are receiving carboplatin with or without bevacizumab.***

IMAGING SECONDARY OBJECTIVES:

I. To determine whether larger changes in tumor perfusion parameters from baseline T0 to
intermediate T1 and from T1 to T2 are prognostic of higher PFS-6 in patients treated with
weekly or every-3-week paclitaxel regimens, who are receiving carboplatin with or without
bevacizumab.*** II. To determine whether larger changes in tumor perfusion parameters values
from T0 to T1, T0 to T2, and T1 to T2 are prognostic of better overall survival in all
treatment arms.*** III. To assess the association between changes in tumor perfusion
parameters before and after chemotherapy initiation (T0 to T1) and subsequent best tumor
response according to standard anatomic Response Evaluation Criteria in Solid Tumors
(RECIST).*** IV. To assess the association between tumor perfusion parameters before
chemotherapy and subsequent best tumor response according to RECIST, PFS-6, and overall
survival.*** V. To test the assumption that tumor perfusion parameters are reliable,
user-independent, and reproducible parameters of tumor microvascular characteristics; a
subgroup of 15 patients will have repeat computed tomography (CT) perfusion studies at the
intermediate T1 time point.***

NOTE: ***Patients enrolled after February 8, 2012 must participate in the ACRIN 6695
component at ACRIN-qualified institutions.

OUTLINE: Patients are randomized to 1 of 2 treatment arms (beginning on 04-30-2012, the trial
is no longer randomized and the chemotherapy regimen is selected and declared prior to
enrolling in the study).

ARM I (adjuvant chemotherapy suboptimally debulked): Patients receive paclitaxel
intravenously (IV) over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment
repeats every 21 days for 6 courses.

ARM II (neoadjuvant chemotherapy with interval cytoreductive surgery): Patients receive
paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1.
Treatment repeats every 21 days for 6 courses. Patients undergo interval cytoreductive
surgery between courses 3 and 4.

Patients in both arms may receive optional** bevacizumab IV over 30-90 minutes on day 1
beginning in course 2. Courses of bevacizumab repeat every 21 days in the absence of disease
progression or unacceptable toxicity. Patients in Arm II receive bevacizumab during courses
2, 5, and 6 only.

NOTE: **Before enrolling onto this study, each patient chooses whether the study treatment
will include concurrent and maintenance bevacizumab.

After completion of study treatment, patients are followed up every 3 months for 2 years,
every 6 months for 3 years, and then annually thereafter.

Inclusion Criteria:

- Primary Surgery and Neoadjuvant Chemotherapy with Interval Cytoreductive Surgery
Patients:

- Patients must have measurable disease; at least one target lesion must have a minimum
length of 1 cm in both the long and short axis (determined at the local site); for
primary surgery patients, if no radiographic evidence of measurable disease is
obtained prior to registration this can be based on surgical findings; imaging then
would need to be completed in the 14 days between Gynecology Oncology Group (GOG)
registration and chemotherapy initiation

- After GOG registration, the American College of Radiology [ACR] Imaging Core
Laboratory will confirm target lesion as required per protocol; the
GOG-eligibility (RECIST) scan and baseline T0 perfusion CT scans will be reviewed
prior to the intermediate T1 perfusion CT time point

- Primary Surgery Patients:

- Patients with a histologic diagnosis of epithelial ovarian cancer, peritoneal primary
carcinoma or fallopian tube cancer, stage II -IV suboptimally debulked (any residual
disease > 1 cm); International Federation of Gynecology and Obstetrics (FIGO) stage is
assessed following the completion of initial abdominal surgery, appropriate imaging
studies and with appropriate tissue available for histologic evaluation; the minimum
surgery required is an abdominal surgery providing tissue for histologic evaluation
and establishing and documenting the primary site and stage; if additional surgery was
performed, it should have been in accordance with appropriate surgery for ovarian or
peritoneal carcinoma described in the GOG Surgical Procedures Manual

- Neoadjuvant Chemotherapy (NAC) with Interval Cytoreductive Surgery (ICS) Patients:

- For patients undergoing NAC-ICS, a core tissue (not fine needle aspiration) biopsy is
required; the tissue must be consistent with a Müllerian origin; patients will require
documentation of at least stage II or extraovarian sites of disease acquired via
imaging or surgery (without attempt at cytoreduction)

- Patients with the following histologic epithelial cell types are eligible: serous,
endometrioid, clear cell, mucinous adenocarcinoma, undifferentiated carcinoma, mixed
epithelial carcinoma, transitional cell carcinoma, malignant Brenner's Tumor, or
adenocarcinoma not otherwise specified (N.O.S.); however, the histologic features of
the tumor must be compatible with a primary Müllerian epithelial adenocarcinoma;
patients may have co-existing fallopian tube carcinoma in-situ so long as the primary
origin of invasive tumor is ovarian, peritoneal or fallopian tube; of note, patients
with clear cell and mucinous tumors will be eligible unless there is a higher priority
protocol

- Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl; this ANC cannot
have been induced or supported by granulocyte colony stimulating factors

- Platelets greater than or equal to 100,000/mcl

- Creatinine =< 1.5 x institutional upper limit normal (ULN)

- Bilirubin less than or equal to 1.5 x ULN

- Serum glutamic oxaloacetic transaminase (SGOT) less than or equal to 3 x ULN

- Alkaline phosphatase less than or equal to 2.5 x ULN

- Neuropathy (sensory or motor) less than or equal to Common Terminology Criteria for
Adverse Events (CTCAE) grade 1

- Patients must have a GOG performance status of 0, 1, or 2

- Patients must be entered within 12 weeks of diagnostic/staging surgery

- Patients who have met the pre-entry requirements

- An approved informed consent and authorization permitting release of personal health
information and must be signed by the patient or guardian

- Only applies for patients who elect to receive bevacizumab:

- Patients in this trial may receive ovarian estrogen +/- progestin replacement
therapy as indicated at the lowest effective dose(s) for control of menopausal
symptoms at any time, but not high-dose progestins for management of anorexia
while on protocol-directed therapy or prior to disease progression due to
thrombophlebitis risk

- Prothrombin time (PT) such that international normalized ratio (INR) is =< 1.5
(or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of
therapeutic warfarin for management of venous thrombosis including pulmonary
thromboembolus) and a partial prothrombin time (PTT) < 1.2 times the upper limit
of normal; (heparin, lovenox or alternative anticoagulants are acceptable)

- All patients enrolled into GOG-0262 at sites where ACRIN 6695 is open will be
enrolled in the advanced imaging protocol; patients receiving adjuvant or
neoadjuvant chemotherapy are eligible for ACRIN 6695; the following sentence does
not apply to those patients entered after 02/08/2012: if a patient declines to
participate in the perfusion imaging portion of the protocol, a clinical
rationale for declination of imaging form will be completed as part of the data
submission for ACRIN 6695

- ACRIN 6695 Eligible Patients:

- Confirmation of ACRIN 6695 eligibility after the baseline T0 perfusion computed
tomography (CT) will be assessed by the ACR Imaging Core Lab: At least one target
lesion must have a minimum length of 1 cm in both the long and short axis (as
determined by the local site), at least half of the target lesion must have
attenuation greater than or equal to 10 Hounsfield Units (HU) on the unenhanced
CT, and at least half of the lesion must have maximum enhancement greater than or
equal to 5 HU in the perfusion CT scan (as determined by the ACR Imaging Core
Lab)

Exclusion Criteria:

- Patients with a current diagnosis of borderline epithelial ovarian tumor (formerly
"tumors of low malignant potential") or recurrent invasive epithelial ovarian, primary
peritoneal or fallopian tube cancer treated with surgery only (such as patients with
stage I-A or I-B low grade epithelial ovarian or fallopian tube cancers) are not
eligible; patients with a prior diagnosis of a borderline tumor that was surgically
resected and who subsequently develop an unrelated, new invasive epithelial ovarian,
peritoneal primary or fallopian tube cancer are eligible, provided that they have not
received prior chemotherapy for any ovarian tumor

- Patients who have received prior radiotherapy to any portion of the abdominal cavity
or pelvis; prior radiation for localized cancer of the breast, head and neck, or skin
is permitted, provided that it was completed more than three years prior to
registration, and the patient remains free of recurrent or metastatic disease

- Patients who have received prior chemotherapy for any abdominal or pelvic tumor
including neo-adjuvant chemotherapy for their ovarian, primary peritoneal or fallopian
tube cancer; patients may have received prior adjuvant chemotherapy for localized
breast cancer, provided that it was completed more than three years prior to
registration, and that the patient remains free of recurrent or metastatic disease

- Patients who have received any targeted therapy (including but not limited to
vaccines, antibodies, tyrosine kinase inhibitors) or hormonal therapy for management
of their epithelial ovarian, fallopian tube or peritoneal primary cancer

- Patients with synchronous primary endometrial cancer, or a past history of primary
endometrial cancer, unless all of the following conditions are met: stage not greater
than I-A, grade 1 or 2, no more than superficial myometrial invasion, without vascular
or lymphatic invasion; no poorly differentiated subtypes, including papillary serous,
clear cell or other FIGO grade 3 lesions

- With the exception of non-melanoma skin cancer, patients with other invasive
malignancies who had (or have) any evidence of the other cancer present within the
last five years or whose previous cancer treatment contraindicates this protocol
therapy

- Patients with acute hepatitis or active infection that requires parenteral antibiotics

- Patients with clinically significant cardiovascular disease; this includes:

- Myocardial infarction or unstable angina < 6 months prior to registration

- New York Heart Association (NYHA) grade II or greater congestive heart failure

- Serious cardiac arrhythmia requiring medication; this does not include
asymptomatic, atrial fibrillation with controlled ventricular rate

- Patients who are pregnant or nursing; patients of childbearing potential must agree to
use contraceptive measures during study therapy and for at least six months after
completion of bevacizumab therapy

- Patients who have received prior therapy with any anti-vascular endothelial growth
factor (VEGF) drug, including bevacizumab

- Patients with medical history or conditions not otherwise previously specified which
in the opinion of the investigator should exclude participation in this study; the
investigator should feel free to consult the Statistical and Data Center (SDC)
randomization desk for uncertainty in this regard

- Patients with known allergy to cremophor or polysorbate 80

- Only applies to patients who elect to receive bevacizumab:

- Patients with serious non-healing wound, ulcer, or bone fracture; this includes
history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess
within 28 days; patients with granulating incisions healing by secondary intention
with no evidence of fascial dehiscence or infection are eligible but require weekly
wound examinations

- Patients with active bleeding or pathologic conditions that carry high risk of
bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major
vessels

- Patients with history or evidence upon physical examination of central nervous system
(CNS) disease, including primary brain tumor, seizures not controlled with standard
medical therapy, any brain metastases, or history of cerebrovascular accident (CVA,
stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months
of the first date of treatment on this study

- Patients with CTCAE grade 2 or greater peripheral vascular disease (at least
brief [< 24 hours] episodes of ischemia managed non-surgically and without
permanent deficit)

- Patients with a history of CVA within six months

- Patients with known hypersensitivity to Chinese hamster ovary cell products or other
recombinant human or humanized antibodies

- Patients with clinically significant proteinuria; urine protein should be screened by
urine protein-creatinine ratio (UPCR); the UPCR has been found to correlate directly
with the amount of protein excreted in a 24 hour urine collection; specifically, a
UPCR of 1.0 is equivalent to 1.0 gram of protein in a 24-hour urine collection; obtain
at least 4 ml of a random urine sample in a sterile container (does not have to be a
24-hour urine); send sample to lab with request for urine protein and creatinine
levels (separate requests); the lab will measure protein concentration (mg/dL) and
creatinine concentration (mg/dL); the UPCR is derived as follows: protein
concentration (mg/dL)/creatinine (mg/dL); patients must have a UPCR < 1.0 to allow
participation in the study

- Patients with or with anticipation of invasive procedures as defined below:

- Major surgical procedure, open biopsy or significant traumatic injury within 28
days prior to the first date of bevacizumab therapy (cycle 2)

- Major surgical procedure anticipated during the course of the study; this
includes, but is not limited to abdominal surgery (laparotomy or laparoscopy)
prior to disease progression such as colostomy or enterostomy reversal, secondary
cytoreductive surgery, or second look surgery; please consult with the SDC
Randomization Desk prior to patient entry for any questions related to the
classification of surgical procedures

- Any tissue biopsy, such as a core biopsy, within 7 days prior to the first date
of bevacizumab therapy (cycle 2)

- Patients with clinical symptoms or signs of gastrointestinal obstruction and who
require parenteral hydration and/or nutrition

- Patients with metastasis tumor in the parenchyma of the liver or lungs with proximity
to large vessels which could make the patients at high risk of lethal hemorrhage
during treatment with bevacizumab (ie. hemoptysis, liver rupture)

- ACRIN 6695 Ineligible Patients:

- Patients with contraindication to iodinated contrast for perfusion CT imaging

- Patients who receive Metformin within 48 hours before perfusion CT imaging
We found this trial at
571
sites
?
mi
from
Provo, UT
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
(505) 272-4946
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
330 Brookline Ave
Boston, Massachusetts 02215
617-667-7000
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
?
mi
from
Boston, MA
Click here to add this to my saved trials
800 Washington St
Boston, Massachusetts 02111
(617) 636-5000
Tufts Medical Center Tufts Medical Center is an internationally-respected academic medical center – a teaching...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Bremerton, Washington 98310
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
1300 Jefferson Park Avenue
Charlottesville, Virginia 22908
434-243-6784
University of Virginia Cancer Center We are fortunate in having state of the art clinical...
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
(810) 262-9000
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
?
mi
from
Flint, MI
Click here to add this to my saved trials
Fort Myers, Florida 33901
?
mi
from
Fort Myers, FL
Click here to add this to my saved trials
3551 Roger Brooke Dr
Fort Sam Houston, Texas 78234
(210) 916-4141
Brooke Army Medical Center Brooke Army Medical Center (BAMC) is the Flagship of Army Medicine!...
?
mi
from
Fort Sam Houston, TX
Click here to add this to my saved trials
301 University Blvd
Galveston, Texas 77555
(409) 772-1011
University of Texas Medical Branch Established in 1891 as the University of Texas Medical Department,...
?
mi
from
Galveston, TX
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
(601) 984-1000
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
?
mi
from
Jackson, MS
Click here to add this to my saved trials
524 South Park Street
Kalamazoo, Michigan 49007
(269) 341-7654
Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
(269) 382-2500
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
529 West Markham Street
Little Rock, Arkansas 72205
(501) 686-7000
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
8700 Beverly Blvd # 8211
Los Angeles, California 90048
(1-800-233-2771)
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
300 Community Drive
Manhasset, New York 11030
(516) 562-0100
North Shore University Hospital North Shore-LIJ Health System includes 16 award-winning hospitals and nearly 400...
?
mi
from
Manhasset, NY
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
(804) 828-0450
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
?
mi
from
Richmond, VA
Click here to add this to my saved trials
600 8th Street South
Saint Petersburg, Florida 33701
?
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Seattle, Washington 98104
?
mi
from
Seattle, WA
Click here to add this to my saved trials
1100 Fairview Avenue North
Seattle, Washington 98109
(206) 667-5000
Fred Hutchinson Cancer Research Center At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
825 Eastlake Ave E
Seattle, Washington 98109
(206) 288-7222
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
3900 W Avera Drive
Sioux Falls, South Dakota 57108
(605) 322-4700
Avera Cancer Institute Avera, the health ministry of the Benedictine and Presentation Sisters, is a...
?
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
601 South Sherman Street
Spokane, Washington 99202
(509) 228-1000
Cancer Care Northwest - Spokane South Cancer Care Northwest is the Inland Northwest’s premier cancer...
?
mi
from
Spokane, WA
Click here to add this to my saved trials
808 North 39th Avenue
Yakima, Washington 98902
?
mi
from
Yakima, WA
Click here to add this to my saved trials
98-1079 Moanalua Road
'Aiea, Hawaii 96701
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
1200 Old York Road
Abington, Pennsylvania 19001
(215) 481–2000
Abington Memorial Hospital Abington Memorial Hospital (AMH) is a 665-bed, regional referral center and teaching...
?
mi
from
Abington, PA
Click here to add this to my saved trials
?
mi
from
Akron, OH
Click here to add this to my saved trials
1 Akron General Avenue
Akron, Ohio 44307
?
mi
from
Akron, OH
Click here to add this to my saved trials
Albany, New York 12208
?
mi
from
Albany, NY
Click here to add this to my saved trials
Albuquerque, New Mexico 87106
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
?
mi
from
Allentown, PA
Click here to add this to my saved trials
170 North 1100 East
American Fork, Utah 84003
?
mi
from
American Fork, UT
Click here to add this to my saved trials
Ames, Iowa 50010
?
mi
from
Ames, IA
Click here to add this to my saved trials
Anchorage, Alaska 99508
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anderson, South Carolina 29621
?
mi
from
Anderson, SC
Click here to add this to my saved trials
2000 E Greenville St
Anderson, South Carolina 29621
(864) 512-4640
AnMedical Health Cancer Center Cancer is the general term for a group of more than...
?
mi
from
Anderson, SC
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
734-712-3456
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Ann Arbor, Michigan 48106
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
?
mi
from
Annandale, VA
Click here to add this to my saved trials
Antigo, Wisconsin 54409
?
mi
from
Antigo, WI
Click here to add this to my saved trials
?
mi
from
Antioch, CA
Click here to add this to my saved trials
?
mi
from
Appleton, WI
Click here to add this to my saved trials
Asheville, North Carolina 28816
?
mi
from
Asheville, NC
Click here to add this to my saved trials
1000 Johnson Ferry Rd NE
Atlanta, Georgia 30342
(404) 851-8000
Northside Hospital Northside Hospital-Atlanta (in Sandy Springs) opened in 1970. The original facility had 250...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Attleboro, Massachusetts 02703
?
mi
from
Attleboro, MA
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
720-848-0000
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
(630) 978-6200
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
?
mi
from
Aurora, IL
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
2401 W Belvedere Ave
Baltimore, Maryland 21215
(410) 601-9000
Sinai Hospital of Baltimore Sinai Hospital of Baltimore provides a broad array of high-quality, cost-effective...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
6701 N Charles St
Baltimore, Maryland 21204
(443) 849-2000
Greater Baltimore Medical Center The 255-bed medical center (acute and sub-acute care) is located on...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
22 South Greene Street
Baltimore, Maryland 21201
410-328-7904
University of Maryland Greenebaum Cancer Center The University of Maryland Marlene and Stewart Greenebaum Cancer...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
410-955-5000
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
489 State St
Bangor, Maine 04401
(207) 973-7000
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
?
mi
from
Bangor, ME
Click here to add this to my saved trials
Baton Rouge, Louisiana 70815
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
265 Fremont St
Battle Creek, Michigan 49017
(269) 245-8166
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
?
mi
from
Battle Creek, MI
Click here to add this to my saved trials
Beech Grove, Indiana 46107
?
mi
from
Beech Grove, IN
Click here to add this to my saved trials
205 Palmer Ave.
Bellefontaine, Ohio 43311
937.592.4015
Mary Rutan Hospital The hospital was endowed by the sale of a farm in Ridgeway...
?
mi
from
Bellefontaine, OH
Click here to add this to my saved trials
Bellingham, Washington 98226
?
mi
from
Bellingham, WA
Click here to add this to my saved trials
Bemidji, Minnesota 56601
?
mi
from
Bemidji, MN
Click here to add this to my saved trials
Bend, Oregon 97701
?
mi
from
Bend, OR
Click here to add this to my saved trials
?
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Bettendorf, Iowa 52722
?
mi
from
Bettendorf, IA
Click here to add this to my saved trials
Big Rapids, Michigan 49307
?
mi
from
Big Rapids, MI
Click here to add this to my saved trials
Billings, Montana 59101
?
mi
from
Billings, MT
Click here to add this to my saved trials
Billings, Montana 59102
?
mi
from
Billings, MT
Click here to add this to my saved trials
Billings, Montana 59101
?
mi
from
Billings, MT
Click here to add this to my saved trials
1233 North 30th Street
Billings, Montana 59101
406-237-7000
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
?
mi
from
Billings, MT
Click here to add this to my saved trials
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
900 E Broadway Ave
Bismarck, North Dakota 58501
(701) 530-5550
Mid Dakota Clinic, PC We're your family clinic, with the doctors you know and trust...
?
mi
from
Bismarck, ND
Click here to add this to my saved trials
900 East Broadway
Bismarck, North Dakota 58501
701.530.7000
Saint Alexius Medical Center St. Alexius Medical Center is a 306-bed, full-service, acute care medical...
?
mi
from
Bismarck, ND
Click here to add this to my saved trials
300 N. Seventh St.
Bismarck, North Dakota 58501
(701) 323-6000
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
?
mi
from
Bismarck, ND
Click here to add this to my saved trials
Bloomington, Illinois 61701
?
mi
from
Bloomington, IL
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
309-662-2102
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
?
mi
from
Bloomington, IL
Click here to add this to my saved trials
?
mi
from
Boise, ID
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
55 Fruit St
Boston, Massachusetts 02114
(617) 724-4000
Massachusetts General Hospital Cancer Center An integral part of one of the world
?
mi
from
Boston, MA
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
(406) 414-5000
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
?
mi
from
Bozeman, MT
Click here to add this to my saved trials
?
mi
from
Brainerd, MN
Click here to add this to my saved trials
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
Bridgeport, Connecticut 06606
?
mi
from
Bridgeport, CT
Click here to add this to my saved trials
Brightwaters, New York 11718
?
mi
from
Brightwaters, NY
Click here to add this to my saved trials
?
mi
from
Bronx, NY
Click here to add this to my saved trials
?
mi
from
Brooklyn, NY
Click here to add this to my saved trials
130 S Bryn Mawr Ave
Bryn Mawr, Pennsylvania 19010
(484) 337-3000
Bryn Mawr Hospital Bryn Mawr Hospital, a nationally recognized community teaching hospital, is conveniently located...
?
mi
from
Bryn Mawr, PA
Click here to add this to my saved trials
?
mi
from
Burbank, CA
Click here to add this to my saved trials
Burlington, Massachusetts 01805
?
mi
from
Burlington, MA
Click here to add this to my saved trials
Burlington, North Carolina 27216
?
mi
from
Burlington, NC
Click here to add this to my saved trials
Burlington, Vermont 05405
?
mi
from
Burlington, VT
Click here to add this to my saved trials
201 E Nicollet Blvd
Burnsville, Minnesota 55337
(952) 892-2000
Fairview Ridges Hospital Fairview Ridges Hospital is a 150-bed, Level III Trauma Care facility, offering...
?
mi
from
Burnsville, MN
Click here to add this to my saved trials
400 South Clark Street
Butte, Montana 59701
406-723-2500
Saint James Community Hospital and Cancer Treatment Center St. James Healthcare has played an important...
?
mi
from
Butte, MT
Click here to add this to my saved trials
?
mi
from
Camden, NJ
Click here to add this to my saved trials
210 W Walnut St
Canton, Illinois 61520
309-647-5240
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
?
mi
from
Canton, IL
Click here to add this to my saved trials
Canton, Illinois 61520
?
mi
from
Canton, IL
Click here to add this to my saved trials
2600 Sixth St. SW
Canton, Ohio 44710
330.363.4908
Aultman Health Foundation The Aultman Foundation will raise and administer funds in order to support...
?
mi
from
Canton, OH
Click here to add this to my saved trials
160 S Adams St
Carthage, Illinois 62321
(217) 357-6877
Illinois CancerCare - Carthage Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
?
mi
from
Carthage, IL
Click here to add this to my saved trials
1454 North County Road 2050
Carthage, Illinois 62321
(217) 357-8500
Memorial Hospital Memorial Hospital is a vital force in establishing and maintaining the well-being of...
?
mi
from
Carthage, IL
Click here to add this to my saved trials
6501 E 2nd St
Casper, Wyoming 82609
(307) 235-5433
Rocky Mountain Oncology Rocky Mountain Oncology Center is a spacious, comfortable, state-of-the-art 19,000 square foot...
?
mi
from
Casper, WY
Click here to add this to my saved trials
20055 Lake Chabot Rd #130
Castro Valley, California 94546
(510) 888-0657
Valley Medical Oncology Consultants - Castro Valley Valley Medical Oncology Consultants (VMOC) has been helping...
?
mi
from
Castro Valley, CA
Click here to add this to my saved trials
20126 Stanton Ave
Castro Valley, California 94546
(510) 581-0556
East Bay Radiation Oncology Center East Bay Radiation Oncology Center offers superior medical and technical...
?
mi
from
Castro Valley, CA
Click here to add this to my saved trials